Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

The game-changing weight loss jabs have ushered in a new era in the war on obesity, but have also been linked to other health ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

Roughly 16 million American adults are taking GLP-1 medications. They are a major breakthrough for people to shed pounds and ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Research from ENDO 2025 reveals that GLP-1 anti-obesity medications not only aid in weight loss but also improve testosterone ...